Day: August 6, 2020

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) — Photon Control Inc. (“Photon Control” or the “Company”) (TSX: PHO), a leading manufacturer of fiber optic measurement solutions to the semiconductor industry, is pleased to announce its financial results for the three and six months ended June 30, 2020.Q2 2020 Highlights:Revenue of $16.1 million versus $7.1 million in Q219Earnings before finance income, accretion expense, income taxes, depreciation, amortization and foreign exchange gain or loss (“EBITDA”)1 of $5.9 million or 37% of revenue versus $1.2 million in Q219;Net income of $2.7 million versus $0.1 million in Q219;Cash and cash equivalents of $41.1 million at June 30, 2020 increased $7.7 million from December 2019;Announced the acquisition of Micronor and the strategic partnership with FiSens.The Company’s revenues...

Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy™ Expected in 2H 2020  MolMed and GSK Agreements Provide Near-term Manufacturing Capacity and Highlight Future InnovationsNear-term Financial Position Secure with Cash and Investments of ~$230M and Runway into 2022BOSTON and LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reviewed business updates and upcoming milestones supporting its new strategic plan and reported financial results for the quarter ended June 30, 2020.“Implementing Orchard’s new strategic plan yielded strong results in the second quarter as we marked important regulatory and clinical progress in our neurometabolic programs and strengthened our current and...

ORLANDO, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (Nasdaq: GENC) announced today net revenues of $22.9 million for the quarter ended June 30, 2020 compared to $18.8 million for the quarter ended June 30, 2019.  Gross margins were 23.5% for the quarter ended June 30, 2020 compared to 25.2% for the quarter ended June 30, 2019, as the gross profit margins achieved in the current quarter were impacted by a higher percentage of revenues generated from plant and equipment sales compared with parts sales, which have a higher gross margin. Product engineering and development expenses decreased $32,000 to $849,000 for the quarter ended June 30, 2020, on reduced travel expenses. Selling, general and administrative (“SG&A”) expenses increased $51,000 to $2,522,000 for the quarter ended June 30, 2020. Increases in sales...

CALGARY, Alberta, Aug. 06, 2020 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announced today its financial and operating results for the second quarter of 2020.SECOND QUARTER 2020 RESULTS(Stated in Canadian dollars except per share and unit data)(1)  Weighted average shares outstanding during the year.Questor’s Consolidated Financial Statements and Management’s Discussion and Analysis for the three and six months ended June 30, 2020 are available on the Company’s website at www.questortech.com and through SEDAR at www.sedar.com.PRESIDENTS MESSAGEThis quarter our revenue declined by 86% from $7.34 million to $1.03 million. For the six months ended June 30th, 2020, our revenue was $5.52 million, a 63% decline from the same period last year. In the first half of the year we have lived within...

BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.“The launch of AMZEEQ® earlier in 2020, together with the recent FDA approval for ZILXI™ underscore the value of our technology platform and serve to consolidate our position as a fully integrated company with strong commercial capabilities in the dermatology space,” said Dave Domzalski, Chief Executive Officer of Menlo. “We are encouraged by the most recent trends in the AMZEEQ launch. Although we experienced some disruption as a result of the pandemic, our field force...

Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 MillionEWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported operating and financial results for the second quarter ended June 30, 2020 with record second quarter revenue of $32.4 million and net income of $2.2 million, or earnings per share of $0.01.  The Company also reported record six-month year-to-date revenue of $65.5 million, a 27% increase versus the first six months of 2019.“I am very proud of the Antares team for delivering strong quarterly results while navigating...

LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2020.“We have had a busy second quarter with data updates across our portfolio at key medical and scientific conferences,” said Dr Christian Itin, chairman and chief executive officer of Autolus.   “Both our later stage programs, AUTO1 and AUTO3, continue to show encouraging clinical activity with tolerable safety in adult patients with ALL and DLBCL, respectively, and we are excited by the potential for these product candidates to have differentiated profiles addressing indications with high unmet needs.  We look forward to providing further updates in H2 2020,...

—ORLADEYO™ (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021——200 mg/400mg BCX9930 data from treatment-naïve PNH patients expected in Q3 2020, 200 mg/400mg data from poor-responders to C5 inhibitors expected by year end 2020 ——Information from Part 1 of galidesivir trial in COVID-19 patients expected by end of Q3 2020—                                                                     RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2020, and provided a corporate update.“BioCryst is currently in an exciting transformation from a company primarily focused on R&D to one that is about to launch its first oral drug to patients with HAE (ORLADEYO) this year, generating...

Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on trackContinued momentum in building commercialization infrastructure and supply chain for Oral PaclitaxelAnnounced two financing agreements for up to $275 million in aggregateProduct sales guidance for 2020 raised to mid-teens percentage growth y/yConference call and live webcast at 8.00am ET todayBUFFALO, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business highlights for the second quarter ended June 30, 2020.“So far, 2020 has been a very productive year at Athenex. We continued to make advancement in our two lead products, Oral...